+39 02 610346.1 - info@newron.com Glossary | Sitemap | Cookie policy Home About Us Research and Drug Development Investors and Media Contact Us Analyst report ‹ › Discovering and developing innovative therapeutics for CNS disorders Welcome to the Newron Pharmaceuticals website. We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain. LATEST PRESS RELEASES 7 OCT Newron raises CHF26.1 Mio. in a private placement of new shares 7 OCT Newron raises CHF26.1 Mio. in a private placement of new shares 6 OCT Newron launches a private placement of new shares 6 OCT Newron launches a private placement of new shares 22 SEP Newron re-submits US NDA for Xadago® (safinamide) 15 SEP Newron reports half-year 2016 results View All NEWRON SHARE PRICE EVENTS 29 NOV 28th Annual Piper Jaffray Healthcare Conference November 29 and 30, 2016 - The Lotte New York Palace, New York - USA 22 NOV German Equity Forum (Deutsches Eigenkapitalforum) November 21-23, 2016 - Frankfurt-am-Main - Germany 23 AUG Bellevue Healthcare Day August 23, 2016 - Marriott Hotel, Zurich, Switzerland View Event Calendar About Us Overview Strategy Our people History Research & Drug Development Therapeutic Focus Pipeline Partners Publications Media News Events Reports, presentations & webcasts Email alert Investors Stock information Financial Calendar Financial Report Shareholder FAQs Disclaimer © Newron 2013. All Rights Reserved